Clinical trials: Chronic Kidney Disease, Receiving Dialysis
Chronic Kidney Disease, Hyperparathyroidism
Pediatric Chronic Kidney Disease Safety and Efficacy
The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the current treatment of secondary hyperparathyroidism in children currently receiving dialysis compared to a treatment regimen that does not…
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease
- Trial name
- NCT01277510
- Testing
- cinacalcet capsule, Standard of Care
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 43 people
- Sponsor
- Amgen
Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism
Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet
Managing bone and mineral disorders associated with chronic kidney disease (CKD-MBD) in children is a complex task. Controlling parathyroid hormone (PTH) levels involves adjusting calcium intake, managing hyperphosphatemia…
- Trial name
- Cin-ca (NCT07007338)
- Testing
- Supplementary blood samples and urines samples
- Where
- 7 sites in France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Chronic Kidney Disease, Kidney Disease
Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients not on dialysis.
- Trial name
- NCT00112008
- Testing
- De Novo Administration of Darbepoetin Alfa
- Volunteers
- 100 people
- Sponsor
- Amgen
Anemia, Chronic Renal Failure
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
The purpose of this study is to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease who are on dialysis and are not taking any treatment to increase their red…
- Conditions
- Anemia, Chronic Renal Failure, Chronic Kidney Disease
- Trial name
- NCT00680043
- Testing
- peginesatide, Epoetin Alfa
- Where
- 11 sites in Russia
- Volunteers
- 114 people
- Sponsor
- Affymax
Chronic Kidney Disease, Receiving Dialysis
Study of South African Dialysis Patients
An observational study to describe the treatment of anaemia in patients with chronic kidney disease, who are receiving dialysis treatment at selected study centres in South Africa.
- Trial name
- NCT01890577
- Testing
- Aranesp
- Where
- 7 sites in South Africa
- Volunteers
- 28 people
- Sponsor
- Amgen
Anemia, Chronic Kidney Disease
Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)
The primary objective of study is Part A : To explore the optimal fixed starting dose and dosing interval of GX-E2 Part B : To evaluate the proof of concept (POC) of GX-E2
- Trial name
- NCT02044653
- Testing
- GX-E2, NESP, MIRCERA
- Where
- 5 sites in South Korea
- Volunteers
- 257 people
- Sponsor
- Genexine, Inc.
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities
This is a multicenter, prospective, observational real-world study designed to evaluate clinical effectiveness, quality of life, and healthcare resource utilization in patients with end-stage renal disease (ESRD) initiating…
- Trial name
- NCT07781124
- Testing
- Remote patient monitoring-automated peritoneal (RPM-APD), Manual peritoneal dialysis (PD) cohort, Maintenance hemodialysis (HD)
- Where
- 20 sites in China
- Volunteers
- 750 people
- Sponsor
- Vantive Health LLC
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate.
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
- Trial name
- RESPOND-2 (NCT06933472)
- Testing
- AP301, AP301 Low Dose
- Where
- 42 sites in United States, China
- Volunteers
- 264 people
- Sponsor
- Alebund Pharmaceuticals
End Stage Renal Disease
Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients
Many children with end stage renal disease develop hyperlipidemia. HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, such as pravastatin, are typical treatments for hyperlipidemia.
- Trial name
- NCT00571194
- Testing
- pravastatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Chronic Kidney Diseases, Colon Polyp
Low-volume vs High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis
Current American Society for Gastrointestinal Endoscopy (ASGE) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend a split regimen of high-volume (4-liter polyethylene glycol-based preparation) or…
- Conditions
- Chronic Kidney Diseases, Colon Polyp, Dialysis; Complications, Colon Cancer
- Trial name
- PrepDial (NCT04709770)
- Testing
- 2-liters polyethylene glycol with citrate and simethicone, 4-liters polyethylene glycol with simethicone, Low-residue diet
- Volunteers
- 264 people
- Sponsor
- Alfredo Di Leo
Renal Insufficiency, Chronic
Impact of Physical Activity on Patients With Chronic Kidney Disease Not Receiving Dialysis Followed in the TIRCEL Network. An Exposed / Unexposed Study (PHYSALYS)
PHYSALYS is an observational multicenter study. It's an analytical study comparing 2 groups: patients exposed to physical activity and unexposed.
- Trial name
- PHYSALYS (NCT02818010)
- Testing
- Global Physical Activity Questionnaire
- Volunteers
- 259 people
- Sponsor
- Hospices Civils de Lyon
ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD)
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
This Phase 3 clinical trial is the pivotal study of AP301 aiming to evaluate the efficacy and safety of AP301 for controlling serum phosphorus in chronic kidney disease receiving hemodialysis and peritoneal dialysis in Chinese…
- Conditions
- ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD), Hyperphosphatemia, Hyperphosphatemia in Chronic Kidney Disease
- Trial name
- RESPOND-1 (NCT07030595)
- Testing
- AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose
- Where
- 50 sites in China
- Volunteers
- 474 people
- Sponsor
- Alebund Pharmaceuticals
Atrial Fibrillation, Atrial Flutter
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)
People receiving dialysis are more likely to develop atrial fibrillation (AF), an irregular heartbeat that increases the risk of stroke.
- Conditions
- Atrial Fibrillation, Atrial Flutter, End Stage Kidney Disease (ESRD), Dialysis Patients
- Trial name
- SAFE-D2 (NCT07779746)
- Testing
- Eliquis, No oral anticoagulation
- Volunteers
- 848 people
- Sponsor
- Unity Health Toronto
Anemia
A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.
This single arm study will evaluate the hemoglobin (Hb) increasing effect, safety and tolerability of two-weekly intravenous administration of Mircera in dialysis patients with chronic renal anemia not currently treated with…
- Trial name
- NCT00737711
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 16 sites in India
- Volunteers
- 189 people
- Sponsor
- Hoffmann-La Roche
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Kidney Disease, Chronic, Diabetes
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population.
- Conditions
- Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
- Trial name
- GUARD-1 (NCT07017270)
- Testing
- Semaglutide Pen
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Unity Health Toronto
End Stage Renal Failure, Hemodialysis
Exploring Predictors of Quality of Life in Older Adults With End-Stage Kidney Disease Receiving In-Center Hemodialysis
This cross-sectional observational study investigates the overall quality of life (QoL) in adults aged 65 and older receiving in-center hemodialysis.
- Trial name
- B670201837264 (NCT07129083)
- Testing
- Structured assessment interview
- Where
- Belgium
- Volunteers
- 111 people
- Sponsor
- University Ghent
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
This single arm study will assess the efficacy and safety of intravenous Mircera, administered with pre-filled syringes, for the treatment of anemia in patients with chronic kidney disease who are on dialysis, and who have…
- Trial name
- NCT00413894
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 105 sites in Germany
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease
EPO Deep Tank in Dialysis Subjects
Subject incidence of adverse events
- Trial name
- NCT00156949
- Testing
- Epoetin alfa DT
- Volunteers
- 580 people
- Sponsor
- Amgen
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with stage 5 CKD receiving Peritoneal…
- Trial name
- NCT04064827
- Testing
- Paricalcitol
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 2 people
- Sponsor
- AbbVie